Literature DB >> 30677460

Central role of the β-cell in driving regression of diabetes after liver transplantation in cirrhotic patients.

Valeria Grancini1, Maddalena Trombetta2, Maria Elena Lunati1, Maria Linda Boselli2, Stefano Gatti3, Maria Francesca Donato4, Eva Palmieri1, Veronica Resi1, Giuseppe Pugliese5, Riccardo C Bonadonna6, Emanuela Orsi7.   

Abstract

BACKGROUND & AIMS: Diabetes occurring as a direct consequence of loss of liver function is usually characterized by non-diabetic fasting plasma glucose (FPG) and haemoglobin A1c (HbA1c) levels and should regress after orthotopic liver transplantation (OLT). This observational, longitudinal study investigated the relationship between the time-courses of changes in all 3 direct determinants of glucose regulation, i.e., β-cell function, insulin clearance and insulin sensitivity, and diabetes regression after OLT.
METHODS: Eighty cirrhotic patients with non-diabetic FPG and HbA1c levels underwent an extended oral glucose tolerance test (OGTT) before and 3, 6, 12 and 24 months after OLT. The OGTT data were analysed with a mathematical model to estimate derivative control (DC) and proportional control (PC) of β-cell function and insulin clearance (which determine insulin bioavailability), and with the Oral Glucose Insulin Sensitivity (OGIS)-2 h index to estimate insulin sensitivity.
RESULTS: At baseline, 36 patients were diabetic (45%) and 44 were non-diabetic (55%). Over the 2-year follow-up, 23 diabetic patients (63.9%) regressed to non-diabetic glucose regulation, whereas 13 did not (36.1%); moreover, 4 non-diabetic individuals progressed to diabetes (9.1%), whereas 40 did not (90.9%). Both DC and PC increased in regressors (from month 3 and 24, respectively) and decreased in progressors, whereas they remained stable in non-regressors and only PC decreased in non-progressors. Insulin clearance increased in all groups, apart from progressors. Likewise, OGIS-2 h improved at month 3 in all groups, but thereafter it continued to improve only in regressors, whereas it returned to baseline values in the other groups.
CONCLUSIONS: Increased insulin bioavailability driven by improved β-cell function plays a central role in favouring diabetes regression after OLT, in the presence of a sustained improvement of insulin sensitivity. LAY
SUMMARY: Diabetes occurring in cirrhosis as a direct consequence of loss of liver function should regress after transplantation of a new functioning liver, though the pathophysiological mechanisms are unclear. This is the first study evaluating the contribution of all 3 direct determinants of insulin-dependent glucose regulation using a sophisticated mathematical model. Results show that β-cell function is the key process governing favourable or detrimental changes in glucose regulation in cirrhotic patients undergoing transplantation, pointing to the need to develop therapies to sustain β-cell function in these individuals. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02038517.
Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatogenous diabetes; Insulin resistance; Liver cirrhosis; Orthotopic liver transplantation; β-cell dysfunction

Year:  2019        PMID: 30677460     DOI: 10.1016/j.jhep.2019.01.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

Review 1.  Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management.

Authors:  Maja Cigrovski Berkovic; Lucija Virovic-Jukic; Ines Bilic-Curcic; Anna Mrzljak
Journal:  World J Gastroenterol       Date:  2020-06-07       Impact factor: 5.742

Review 2.  Medical management of metabolic and cardiovascular complications after liver transplantation.

Authors:  Chiara Becchetti; Melisa Dirchwolf; Vanessa Banz; Jean-François Dufour
Journal:  World J Gastroenterol       Date:  2020-05-14       Impact factor: 5.742

3.  An Analysis of the Risk Factors for New-Onset Diabetes Mellitus After Liver Transplantation.

Authors:  Jushan Sun; Yibiao He; Lei Bai; Zhipeng Wang; Zhu Cao; Yingmei Shao; Jinming Zhao
Journal:  Int J Gen Med       Date:  2021-08-24

4.  Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis.

Authors:  Claudia Piona; Enza Mozzillo; Antonella Tosco; Sonia Volpi; Francesco Maria Rosanio; Chiara Cimbalo; Adriana Franzese; Valeria Raia; Chiara Zusi; Federica Emiliani; Maria Linda Boselli; Maddalena Trombetta; Riccardo Crocina Bonadonna; Marco Cipolli; Claudio Maffeis
Journal:  J Clin Med       Date:  2022-07-17       Impact factor: 4.964

Review 5.  Hepatogenous diabetes: Knowledge, evidence, and skepticism.

Authors:  Ramesh Kumar; Diego García-Compeán; Tanmoy Maji
Journal:  World J Hepatol       Date:  2022-07-27

Review 6.  Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease.

Authors:  Angelo Armandi; Chiara Rosso; Gian Paolo Caviglia; Elisabetta Bugianesi
Journal:  Metabolites       Date:  2021-03-08

7.  The IGFBP3/TMEM219 pathway regulates beta cell homeostasis.

Authors:  Francesca D'Addio; Anna Maestroni; Emma Assi; Moufida Ben Nasr; Giovanni Amabile; Vera Usuelli; Cristian Loretelli; Federico Bertuzzi; Barbara Antonioli; Francesco Cardarelli; Basset El Essawy; Anna Solini; Ivan C Gerling; Cristina Bianchi; Gabriella Becchi; Serena Mazzucchelli; Domenico Corradi; Gian Paolo Fadini; Diego Foschi; James F Markmann; Emanuela Orsi; Jan Škrha; Maria Gabriella Camboni; Reza Abdi; A M James Shapiro; Franco Folli; Johnny Ludvigsson; Stefano Del Prato; Gianvincenzo Zuccotti; Paolo Fiorina
Journal:  Nat Commun       Date:  2022-02-03       Impact factor: 17.694

8.  High Albumin Level Is Associated With Regression of Glucose Metabolism Disorders Upon Resolution of Acute Liver Inflammation in Hepatitis B-Related Cirrhosis.

Authors:  Caiyun Tian; Yanping Zhu; Yujuan Liu; Han Hu; Qijiao Cheng; Fangwan Yang; Lingqi Pei; Yihong Zhou; Ying Li; Shide Lin
Journal:  Front Cell Infect Microbiol       Date:  2022-02-22       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.